Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study ; volume:16 ; number:1 ; day:18 ; month:8 ; year:2015 ; pages:1-11 ; date:12.2015
Respiratory research ; 16, Heft 1 (18.8.2015), 1-11, 12.2015
- Creator
-
O’Byrne, Paul M.
- Contributor
-
D’Urzo, Tony
Beck, Ekkehard
Fležar, Matjaž
Gahlemann, Martina
Hart, Lorna
Blahova, Zuzana
Toorawa, Robert
Beeh, Kai-Michael
SpringerLink (Online service)
- DOI
-
10.1186/s12931-015-0249-8
- URN
-
urn:nbn:de:1111-201611086378
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- O’Byrne, Paul M.
- D’Urzo, Tony
- Beck, Ekkehard
- Fležar, Matjaž
- Gahlemann, Martina
- Hart, Lorna
- Blahova, Zuzana
- Toorawa, Robert
- Beeh, Kai-Michael
- SpringerLink (Online service)
Other Objects (12)
A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
Correction: First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study
Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study
A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
Correction: First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study
Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study
A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic–pituitary–adrenocortical axis of children with asthma
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
Correction: First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study
Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study